Mesoblast Limited or Geron Corporation: Who Leads in Yearly Revenue?

Mesoblast vs. Geron: A Revenue Showdown

In the competitive landscape of biotechnology, Mesoblast Limited and Geron Corporation have been vying for dominance in yearly revenue since 2014. Mesoblast has consistently outperformed Geron, with revenues peaking at approximately $42.5 million in 2016, a staggering 590% higher than Geron's peak in 2015. Over the years, Mesoblast's revenue has shown resilience, maintaining an average of $17.5 million annually, while Geron has struggled to keep pace, averaging just $4.9 million.

A Decade of Revenue Trends

From 2014 to 2023, Mesoblast's revenue trajectory has been relatively stable, with a notable dip in 2017. In contrast, Geron's revenue has been more volatile, with a significant spike in 2015 followed by a steady decline. The data for 2024 is incomplete, but the trend suggests Mesoblast's continued leadership. This revenue analysis highlights the dynamic nature of the biotech industry and the challenges companies face in sustaining growth.